INNOVA CAPTAB Latest Share Price (INNOVACAP)
TODAY IN ONE LINE
INNOVACAP fell 1.7% on light volume, lagging Nifty's -0.3% move, supported by recent strong earnings.
With a market cap of ₹6,598.61 Cr., it trades at a P/E of 42.22. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
INNOVA CAPTAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 28.6% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 17.6% and Profit up 37.6%
- ●High Promoter HoldingPromoters hold 50.9% skin-in-the-game
Red Flags
- ●Poor Capital ReturnsLow ROE of 9.4%
- ●Rising Receivables vs SalesReceivables grew 20.7% outpacing sales growth of 15.0%
- ●Promoter Pledging DetectedPledge activity recorded on 30-Sep-2025 14:08
Latest INNOVA CAPTAB News
What changed recently?
Recent events, corporate actions, and announcements.
INNOVA CAPTAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for INNOVA CAPTAB, framed against the sector median so the premium or discount is obvious at a glance.
INNOVA CAPTAB trades at a P/E of 42.22× and P/B of 6.10×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
INNOVA CAPTAB technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for INNOVA CAPTAB — derived from the latest tape, not yesterday's close.
INNOVA CAPTAB last traded at ₹1,147.2 with an intraday range of ₹1,133.1–₹1,168.1 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1147.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1235.83 | +88.63 | +7.73% |
| R3 | 1200.83 | +53.63 | +4.68% |
| R2 | 1184.47 | +37.27 | +3.25% |
| R1 | 1165.83 | +18.63 | +1.62% |
| PIVOT | 1149.47 | 2.27 | 0.20% |
| CURRENT | 1147.20 | — | — |
| S1 | 1130.83 | -16.37 | -1.43% |
| S2 | 1114.47 | -32.73 | -2.85% |
| S3 | 1095.83 | -51.37 | -4.48% |
| S4 | 1060.83 | -86.37 | -7.53% |
INNOVACAP is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹1137.8–₹1168.1
Trading Below opening range, showing Bearishness
INNOVA CAPTAB financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for INNOVA CAPTAB — consolidated or standalone — with margins, YoY growth and key ratios inline.
INNOVA CAPTAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,598.61 Cr. and reported EPS of ₹7.71.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,244 | 1,630 ▲ 31.1% |
| Sales Growth YoY %Derived | 15.02% | 31.06% |
| Other Income | 12 | 7 ▼ 38.4% |
| Total Income | 1,256 | 1,637 ▲ 30.4% |
| 814 | 1,053 ▲ 29.3% | |
| Gross ProfitDerived | 430 | 577 ▲ 34.4% |
| Gross Margin %Derived | 34.54% | 35.41% |
| 243 | 334 ▲ 37.3% | |
| EBITDA (Operating Profit)Derived | 186 | 243 ▲ 30.5% |
| OPM %Derived | 14.97% | 14.90% |
| 27 | 62 ▲ 128.4% | |
| Profit Before Tax (PBT) | 171 | 188 ▲ 10.1% |
| 43 | 45 ▲ 5.4% | |
| Effective Tax %Derived | 25.00% | 23.95% |
| Total Profit for Period | 128 | 143 ▲ 11.6% |
| Net Profit (Owner's PAT)Derived | 128 | 143 ▲ 11.6% |
| Net Profit Margin %Derived | 10.31% | 8.78% |
| PAT Growth YoY %Derived | 35.95% | 11.64% |
| Earnings Per Share (EPS ₹) | 22.41 | 25.02 ▲ 11.6% |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 53.2% |
| Total Expenses (incl. D&A & Interest) | 1,085 | 1,449 ▲ 33.6% |
| Material Cost % of RevenueDerived | 64.31% | 61.68% |
| Employee Cost % of RevenueDerived | 9.39% | 10.26% |
| Other Cost % of RevenueDerived | 10.18% | 10.25% |
| Interest Coverage (x)Derived | 67.10x | 11.70x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 1,081 | 1,244 ▲ 15.0% | 1,630 ▲ 31.1% | |
| Sales Growth YoY %Derived | — | 15.02% | 31.06% | |
| Other Income | 12 | 12 ▼ 3.6% | 7 ▼ 38.4% | |
| Total Income | 1,094 | 1,256 ▲ 14.8% | 1,637 ▲ 30.4% | |
728 | 814 ▲ 11.8% | 1,053 ▲ 29.3% | ||
| Gross ProfitDerived | 353 | 430 ▲ 21.7% | 577 ▲ 34.4% | |
| Gross Margin %Derived | 32.64% | 34.54% | 35.41% | |
199 | 243 ▲ 22.6% | 334 ▲ 37.3% | ||
| EBITDA (Operating Profit)Derived | 154 | 186 ▲ 20.5% | 243 ▲ 30.5% | |
| OPM %Derived | 14.28% | 14.97% | 14.90% | |
37 | 27 ▼ 27.3% | 62 ▲ 128.4% | ||
| Profit Before Tax (PBT) | 130 | 171 ▲ 32.0% | 188 ▲ 10.1% | |
35 | 43 ▲ 21.5% | 45 ▲ 5.4% | ||
| Effective Tax %Derived | 27.16% | 25.00% | 23.95% | |
| Total Profit for Period | 94 | 128 ▲ 35.9% | 143 ▲ 11.6% | |
| Net Profit (Owner's PAT)Derived | 94 | 128 ▲ 35.9% | 143 ▲ 11.6% | |
| Net Profit Margin %Derived | 8.73% | 10.31% | 8.78% | |
| PAT Growth YoY %Derived | — | 35.95% | 11.64% | |
| Earnings Per Share (EPS ₹) | 16.49 | 22.41 ▲ 35.9% | 25.02 ▲ 11.6% | |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% | 6 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 2 | 0 ▼ 86.0% | 0 ▲ 53.2% | |
| Total Expenses (incl. D&A & Interest) | 964 | 1,085 ▲ 12.5% | 1,449 ▲ 33.6% | |
| Material Cost % of RevenueDerived | 64.38% | 64.31% | 61.68% | |
| Employee Cost % of RevenueDerived | 8.38% | 9.39% | 10.26% | |
| Other Cost % of RevenueDerived | 9.97% | 10.18% | 10.25% | |
| Interest Coverage (x)Derived | 6.45x | 67.10x | 11.70x |
INNOVA CAPTAB segment analysis : revenue and profit mix.
Disclosed business segments at INNOVA CAPTAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
INNOVA CAPTAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for INNOVA CAPTAB.
Our AI distills the core fundamental drivers supporting INNOVA CAPTAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
INNOVA CAPTAB's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 55 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
INNOVA CAPTAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — INNOVA CAPTAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
INNOVA CAPTAB chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for INNOVA CAPTAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
INNOVA CAPTAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for INNOVA CAPTAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in INNOVA CAPTAB stood at 54.4% of traded volume, against a 20-day average of 45.2%.
INNOVA CAPTAB announcements: results, concalls, ratings, M&A.
Filings INNOVA CAPTAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
INNOVA CAPTAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 119 documents below.
Copy of Newspaper Publication
Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
Innova Captab Limited has informed the Exchange about General Updates
Shareholders meeting
Innova Captab Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
Copy of Newspaper Publication
Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Innova Captab Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
INNOVA CAPTAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue INNOVA CAPTAB has declared, sequenced by announce and record date.
INNOVA CAPTAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
INNOVA CAPTAB insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in INNOVA CAPTAB as reported to SEBI — buying and selling signals from the people who know the business best.
INNOVA CAPTAB insider activity below tracks 5 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Archit Aggarwal | Insider | 24 Mar 2026 | buy | +43.75 L | ₹302.31 Cr. | ₹691.00 |
| Archit Aggarwal | Insider | 24 Mar 2026 | buy | +43.75 L | ₹302.31 Cr. | ₹691.00 |
| Archit Aggarwal | Insider | 24 Mar 2026 | buy | +43.75 L | ₹302.31 Cr. | ₹691.00 |
| Archit Aggarwal | Insider | 24 Mar 2026 | buy | +43.75 L | ₹302.31 Cr. | ₹691.00 |
| Archit Aggarwal | Insider | 24 Mar 2026 | buy | +43.75 L | ₹302.31 Cr. | ₹691.00 |
About INNOVA CAPTAB: business, sector, key facts.
What INNOVA CAPTAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
INNOVA CAPTAB operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: INNOVACAP, BSE: 544067.
Innova Captab Limited is an integrated pharmaceutical company operating in India and internationally. Its core business encompasses the entire pharmaceutical value chain, from research and development to marketing and distribution of its own products and those of other companies. This vertical integration allows for greater control over quality and efficiency throughout the process.
A significant portion of Innova Captab's business involves contract development and manufacturing organization (CDMO) services. The company provides these services to other Indian pharmaceutical firms, leveraging its manufacturing capabilities and expertise to produce drugs according to their specifications. This aspect of the business generates revenue streams independent of the company's own branded products.
Innova Captab manufactures and distributes a wide range of generic formulation products covering numerous therapeutic areas. These include but are not limited to antibiotics (cephalosporins, fluoroquinolones, macrolides), cardiovascular drugs, analgesics, anti-inflammatory agents, antidiabetic medications, and treatments for various other conditions. The company produces these drugs in diverse forms, including tablets, capsules, syrups, injections, and ointments, showcasing its versatility in pharmaceutical manufacturing.
The company's branded generic products reach the market through a multi-channel distribution strategy. This includes a traditional network of distributors and pharmacies, as well as a growing online presence via e-commerce pharmacy websites. This diversified approach allows Innova Captab to access a broader customer base and enhance market reach.
In summary, Innova Captab Limited operates a multifaceted pharmaceutical business model. It combines CDMO services for other pharmaceutical companies with the development, manufacture, and distribution of its own portfolio of branded generic drugs, achieving market access via both traditional and online channels. This integrated approach positions the company strategically within the competitive Indian and international pharmaceutical markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about INNOVA CAPTAB (INNOVACAP).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of INNOVA CAPTAB (INNOVACAP)?
The current share price of INNOVA CAPTAB (INNOVACAP) is ₹1,147.20. Today, the stock has declined by ₹20.20 (1.73%), trading in a range of ₹1,133.10 to ₹1,168.10. The stock opened at ₹1,150.10 with a trading volume of 44,230 shares.
02Is INNOVA CAPTAB stock a good investment for long-term?
INNOVA CAPTAB can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,598.61 Cr., P/E ratio of 42.22, ROE of 9.44%, and ROCE of 7.89%. The dividend yield stands at 0.17%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of INNOVA CAPTAB stock?
The 52-week high price of INNOVA CAPTAB (INNOVACAP) is ₹1,200.00, while the 52-week low is ₹622.00. Currently trading at ₹1,147.20, the stock is 84.44% above its 52-week low and 4.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy INNOVA CAPTAB stock at the current price?
Whether to buy INNOVA CAPTAB stock at ₹1,147.20 depends on multiple factors. The stock is currently trading with a P/E ratio of 42.22 and P/B ratio of 6.1. Today's performance shows a loss of 1.73%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of INNOVA CAPTAB and when is the next dividend?
INNOVA CAPTAB offers a dividend yield of 0.17%, which means for every ₹100 invested at the current price of ₹1,147.20, you can expect to receive approximately ₹0.17 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of INNOVA CAPTAB?
INNOVA CAPTAB's key financial metrics include: P/E Ratio: 42.22, P/B Ratio: 6.1, ROE: 9.44%, ROCE: 7.89%, Dividend Yield: 0.17%, EPS: ₹7.71, Book Value: ₹188.99, and Debt-to-Equity: 0.36. The company's market cap stands at ₹6,598.61 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is INNOVA CAPTAB stock performing today in the market?
INNOVA CAPTAB stock opened at ₹1,150.10 and is currently trading at ₹1,147.20, showing a decline of ₹20.20 (1.73%). The intraday high is ₹1,168.10 and low is ₹1,133.10. The trading volume stands at 44,230 shares, indicating moderate market participation today.
08What is the P/E ratio of INNOVA CAPTAB and what does it indicate?
INNOVA CAPTAB has a Price-to-Earnings (P/E) ratio of 42.22, which means investors are willing to pay 42.22 for every ₹1 of earnings. With an EPS of ₹7.71, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about INNOVA CAPTAB (INNOVACAP) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.